Lanthanum Carbonate 1000mg Chewable Tablets Recalled for Broken and Crushed Tablets
Cipla USA is recalling Lanthanum Carbonate Chewable Tablets, 1000mg due to complaints of crushed and broken tablets. The recall affects 1,875 boxes distributed nationwide.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall based on failed tablet specifications (crushed and broken tablets). The source documents no associated illnesses, injuries, or hospitalizations. The hazard is a physical defect affecting product integrity rather than chemical or biological safety.
Plain-English summary
Cipla USA, Inc. is recalling Lanthanum Carbonate Chewable Tablets, 1000mg (10-count bottles) due to failed tablet specifications. The company received complaints that tablets in affected lots are crushed or broken.
The recalled product (NDC 69097-0936-98, Lot #NB240316, Exp 12/31/25) was distributed nationwide. The recall affects approximately 1,875 boxes.
The recalled product
- Product
- Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manufactured for Cipla USA, NDC 69097-0936-98
- Manufacturer
- Cipla USA, Inc.
- Category
- Drug — Prescription Medication
- Affected units
- 1,875
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # NB240316
- Exp 12/31/25
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Cipla USA, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Cipla USA, Inc.
See all →- ModerateCipla Recalls Fosfomycin Tromethamine Due to Impurity Specification Failures
FDA (Drugs) · 2026-10-14
- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighCipla cinacalcet 60 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
Same hazard · broken tablets
See all →- HighLanthanum Carbonate Chewable Tablets Recalled for Crushed and Broken Tablets
FDA (Drugs) · 2024-11-20
- ModerateQualitest Recalls Oxycodone and Acetaminophen Tablets Due to Broken Tablets
FDA (Drugs) · 2014-09-10
- ModerateCaraco Recalls Oxcarbazepine Tablets Due to Broken Tablets
FDA (Drugs) · 2014-02-19
- ModerateActavis Recalls Diclofenac Sodium and Misoprostol Tablets Due to Broken Tablets
FDA (Drugs) · 2014-02-12
- ModerateWatson Recalls Hydrocodone and Acetaminophen Tablets Due to Broken Tablets
FDA (Drugs) · 2014-02-05
Similar recalls
- ModerateLanthanum carbonate tablets recalled in a second hardness specification failure
FDA (Drugs) · 2025-12-17
- SevereLanthanum carbonate chewable tablets recalled after failing a hardness specification
FDA (Food) · 2025-12-17
- SevereLanthanum Carbonate Chew Tablets Recalled for Potential Label Mixup
FDA (Drugs) · 2014-01-22
- HighCinacalcet 90 mg tablets recalled over a nitrosamine impurity above limits
FDA (Drugs) · 2025-12-17
- SevereCinacalcet 60 mg tablets recalled over a nitrosamine impurity above limits
FDA (Food) · 2025-12-17
- HighCinacalcet 30 mg tablets recalled over a nitrosamine impurity above limits
FDA (Drugs) · 2025-12-17